News Update

Aug 01, 2001
Pharmaceutical Executive
Brussels-Lack of intellectual property protection is not causing the erosion of European pharma, reports the European Generics Association.
Aug 01, 2001
Pharmaceutical Executive
London-GlaxoSmithKline is proposing to cut more than 2,000 jobs from its worldwide workforce of 100,000 as it seeks to generate the promised savings from its merger.
Aug 01, 2001
Pharmaceutical Executive
Singapore—Lilly’s decision to set up a Singapore R&D center to focus on systems biology is the latest in a series of moves that have put the Far East island on the biotech map.
Jul 01, 2001
Pharmaceutical Executive
Epsom, Surrey, United Kingdom—Pharmaceutical companies struggle to be taken seriously when they talk of facing pressures. A quick look at the bottom line often suggests they are overstating their worries. But new evidence shows they are being squeezed by generic competition and falling R&D output.
Jul 01, 2001
Pharmaceutical Executive
European Union-The European Commission’s ban on GlaxoSmith–Kline’s dual pricing policy in Spain halts one of Big Pharma’s attempts to prevent parallel imports in Europe.
Jul 01, 2001
Pharmaceutical Executive
Basel, Switzerland—Roche, which recently slashed its work force by 3,000, maintains that it will remain independent even after the sale of 20 percent of the company to Novartis. Franz Humer, the troubled company’s chairman, says the founding family supports Roche’s strategy.
Jul 01, 2001
Pharmaceutical Executive
Basel, Switzerland -Novartis plans to provide its malaria drug, Coartem (artemether/lumefantrin), at cost to developing countries in partnership with the World Health Organization (WHO). The effort is only the latest in a series of moves intended to increase access to essential medicines after Big Pharma’s South Africa debacle.
Jul 01, 2001
Pharmaceutical Executive
London, United Kingdom-The UK OTC trade association supports the Community Pharmacy Action Group (CPAG) in its decision to withdraw a court case regarding the price-fixing of OTC drugs after the judge said there was little evidence that abolition of price maintenance would harm community pharmacists. The withdrawal brings an end to a long-running court battle pitting the pharmaceutical industry against an equally powerful corporate enemy, the supermarkets.
Jun 01, 2001
Pharmaceutical Executive
Buckinghamshire, UK-The pharma industry may be countercyclical, but it’s not immune to market trends. Nycomed Amersham recently postponed a partial US stock flotation of its life sciences company, ABBiotech, because of market weakness.
Jun 01, 2001
Pharmaceutical Executive
Schering’s commitment to biotechnology in the early 1990s was a landmark decision for the company, says Dr. Guiseppe Vita, who is stepping down as chairman of the Berlin-based company. The result of that commitment was Betaferon (interferon beta-Ib), one of the first biotech products on the market in Germany. It is now Schering’s biggest product and one of the top ten best selling biotech therapies in the world.
native1_300x100
lorem ipsum